SC Scathing 'Daylight Robbery' Rebuke Forces Govt Hand: Trade Margins on 110 Cancer Drugs Slashed to 30%

Stung by a scathing judicial rebuke over predatory pricing, the Union government has been forced into action, initiating steps to cap trade margins at 30% for 110 non-scheduled cancer drugs, including 35 patented formulations.

While the policy shift will ultimately bring much-needed relief to patients facing exorbitant out-of-pocket costs, the intervention comes on the back of intense regulatory pressure rather than proactive reform.

The Catalyst: Supreme Court's 'Daylight Robbery' Outcry

The policy pivot was catalyzed by a sharp reprimand from the Supreme Court, which blasted massive hospital and retailer markups as "broad daylight dacoity" and "carnage."

Calling out extreme market distortions, the apex court highlighted instances where vital cancer medicines supplied to retailers for ₹2,700 were being billed to vulnerable patients at a maximum retail price (MRP) of ₹27,000 a staggering 900% markup. Facing mounting judicial scrutiny and public outrage over patients being fleeced during medical emergencies, the administration was compelled to act.

How the Margin Limit Works

According to market data analysed by the National Pharmaceutical Pricing Authority (NPPA), average trade markups for critical cancer drugs sat at roughly 170%, scaling up to 700% in some instances.

• The Mechanism: The trade margin represents the financial gap between the wholesale price at which a manufacturer or importer supplies a drug to distributors and the final MRP paid by the patient at a retail pharmacy or hospital counter.
• The Regulation: Under the mandated cap, the trade margin for the identified list of 110 non-scheduled cancer drugs is restricted to 30%. Compressing this profit spread is projected to drive down MRPs by up to 70% in certain cases, yielding substantial savings for families undergoing prolonged cancer care.

Despite the relief for patients, public health experts point out that the intervention leaves primary manufacturing prices unchecked. Because patented drugs face little to no generic competition, pharmaceutical companies may still find ways to inflate base costs leaving critics to argue that more aggressive public health safeguards, such as compulsory licensing, remain necessary to truly tame cancer drug prices.